News

These posters were intended for scientific discussions at professional conferences. Therefore, the posters are not intended to confer efficacy or safety of Pearl Therapeutics investigational products and are not intended to make comparative claims to open-label active comparators.


European Respiratory Society (ERS) 2013 Annual Meeting

Poster: Pooled Analyses of QTcF across Six Phase IIb Studies with Glycopyrrolate-Formoterol Fumarate (GFF) MDI (PT003), Its Components and Active Comparators (pdf, 1.3mb)

Poster: Eliminating In Vitro Drug-Drug Interactions in Dual and Triple Fixed-Dose Combination Therapies Using a Novel Cosuspension Metered Dose Inhaler Platform (pdf, 1.9mb)

Poster: Sub-Microgram Dose Formulations for Dose Ranging Studies with Long-Acting Bronchodilators and Their Fixed-Dose Combination Using Metered Dose Inhalers (MDIs) (pdf, 688k)

Poster: Pooled Analyses of Phase IIb Studies Support Dose Selection of Glycopyrrolate-Formoterol Fumarate (GFF) MDI (PT003) 18/9.6 μg for Phase III Development (pdf, 1.1mb)

Poster: Integrated Analyses of Phase II Safety Data Support the Safety of Glycopyrrolate-Formoterol Fumarate (GFF) MDI (PT003) and Glycopyrrolate (GP) MDI (PT001) in COPD (pdf, 1.2mb)

American Thoracic Society 2013 International Conference

Poster: Phase 2b Results: Low doses of PT003 demonstrated superior bronchodilation compared to components and open-label Spiriva (pdf, 145k)

Poster: Phase 2b Results: All four doses of glycopyrrolate MDI (PT001) are non-inferior to Atrovent; dose-ranging identifies 18 μg BID as optimal (pdf, 166k)

Poster: Phase 2b Results: Treatment with PT003 not associated with cardiovascular adverse effects, such as change in heart rate (HR). (pdf, 118k)

Poster: Phase 2b Results: Pooled analysis from six studies of glycopyrrolate MDI (PT001) dose-ranging from 0.6 μg to 36 μg BID (pdf, 150k)

American Thoracic Society 2012 International Conference

Poster: Phase 2b Results: PT003 Provides a Significant Benefit on Home Peak Expiratory Flow Rate and Reduces the Need for Rescue Albuterol Use Compared to its Components and Active Controls (pdf, 471k)

Poster: Phase 2b Results: PT003 Provides Comparable Metabolic and ECG Safety to Spiriva® Handihaler® and Placebo in Patients with COPD (pdf, 417k)

Poster: Phase 2b Results: PT003 Provides Similar Systemic Exposure to the Individual MDI Formulations Administered Alone (pdf, 512k)

Poster: Phase 2b Results: PK Bioequivalence and Comparable Efficacy/Safety were Demonstrated with Formoterol Fumarate MDI (PT005) Compared to Foradil® Aerolizer® in Patients with COPD (pdf, 620k)

Poster: Integrated Phase 2 Results: FEV1 and Pharmacokinetic Relationship of Formoterol Fumarate MDI (PT005) and Foradil® Aerolizer® (pdf, 417k)

Poster: Phase 2b Results: Formoterol Fumarate MDI (PT005) Demonstrates Pharmacokinetic Bioequivalence to Foradil® Aerolizer® (pdf, 688k)

Poster: In Vitro Results: Nanogram Level Dose Proportionality and Stability of Glycopyrrolate and Formoterol Fumarate in a Novel Cosuspension MDI Format (pdf, 2.6mb)

Poster: In Vitro Results: Triple Drug Fixed Dose Combination MDI with Stable and Equivalent Drug Delivery Performance Relative to Individual and Dual Subcomponents (pdf, 1.5mb)

Respiratory Drug Delivery (RDD) 2012

Poster: In Vitro Results: High-Sensitivity Analysis of Crystallinity in Respirable Powders Using Low Frequency Shift-Raman Spectroscopy

Poster: In Vitro Results: Product Performance, Stability and Dose Proportionality of Glycopyrrolate MDI with Sub-Microgram Doses Using Cosuspension Technology

Poster: In Vitro Results: The Effect of Valve Storage Conditions on pMDI Water Content

American Association of Pharmaceutical Scientists (AAPS)
2011 Annual Meeting

Poster: In Vitro Structural Data: Thermodynamic and Structural Properties of Porous Particles (pdf, 1.7mb)

Poster: In Vitro Performance Data: Proprietary Formulation Approach Generates Uniform and Stable MDI Cosuspensions (pdf, 780k)

European Respiratory Society (ERS) 2011 Annual Meeting

Poster: Phase 2b Results: PT003 (GFF MDI) Demonstrates Superior Inspiratory Capacity Compared to Tiotropium (pdf, 600k)

Poster: Phase 2b Results: Glycopyrrolate MDI Demonstrates Comparable Efficacy and Safety to Tiotropium (pdf, 300k)

American Thoracic Society 2011 International Conference

Poster: Phase 2b Results: PT003 (GFF MDI) Provides Statistically Significant Improvement in Lung Function vs Tiotropium and Foradil (pdf, 2mb)

Respiratory Drug Delivery (RDD) Europe 2011

Poster: Performance Advantages of Pearl Cosuspension Formulation Technology (pdf, 500k)

Poster: Development of Inhaled Mono, Dual and Triple Combinations without Coformulation Effect (pdf, 3.1mb)

European Respiratory Society Annual Congress 2010

Poster: Phase 1/2a Results: Dose of Glycopyrrolate MDI Identified as Comparable to Approved Dose of Tiotropium (pdf, 1.5mb)

Poster: Phase 1/2a Results: Dose of Formoterol Fumarate MDI Identified as Comparable to Approved Dose of Foradil (pdf, 1.5mb)

American Thoracic Society 2010 International Conference

Poster: Phase 1 Study Results: PT003 (GFF MDI) Combination Bronchodilator Found to be Safe and Well Tolerated (pdf, 1.7mb)

Poster: Phase 1/2a Results: Glycopyrrolate MDI Demonstrates Comparable Efficacy and Safety to Tiotropium (pdf, 1.8mb)

Poster: Phase 1/2a Results: Formoterol Fumarate MDI Demonstrates Comparable Efficacy and Safety to Foradil (pdf, 1.8mb)

Poster: Stability Results: Glycopyrrolate MDI and Formoterol Fumarate MDI Shown to be Physically and Chemically Stable (pdf, 2.7mb)